Yakoub-Agha, Ibrahim and Chabannon, Christian and Bader, Peter and Basak, Grzegorz W. and Bonig, Halvard and Ciceri, Fabio and Corbacioglu, Selim and Duarte, Rafael F. and Einsele, Hermann and Hudecek, Michael and Kersten, Marie Jose and Koehl, Ulrike and Kuball, Juergen and Mielke, Stephan and Mohty, Mohamad and Murray, John and Nagler, Arnon and Robinson, Stephen and Saccardi, Riccardo and Sanchez-Guijo, Fermin and Snowden, John A. and Srour, Micha and Styczynski, Jan and Urbano-Ispizua, Alvaro and Hayden, Patrick J. and Kroeger, Nicolaus (2020) Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). HAEMATOLOGICA, 105 (2). pp. 297-316. ISSN 0390-6078,
Full text not available from this repository. (Request a copy)Abstract
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagen-lecleucel (Kymriah (TM)) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta (TM)) is approved for the treatment of relapsed/refractory high-grade B-cell lymphoma and primary mediastinal B-cell lymphoma. Both agents are genetically engineered autologous T cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting conditioning, product receipt and thawing, infusion of CAR T cells, short-term complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, antibiotic prophylaxis, medium-term complications induding cytopenias and B-cell aplasia, nursing and psychological support for patients, long-term follow-up, post-authorization safety surveillance, and regulatory issues. These recommendations are not prescriptive and are intended as guidance in the use of this novel therapeutic class.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CYTOKINE-RELEASE SYNDROME; HAPLOIDENTICAL DONOR TRANSPLANTATION; HEMATOLOGICAL MALIGNANCIES; PEDIATRIC-PATIENTS; PLASMA-LEVELS; CAR THERAPY; BONE-MARROW; REMISSIONS; TISAGENLECLEUCEL; EXPRESSION; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 01 Apr 2021 07:11 |
| Last Modified: | 01 Apr 2021 07:11 |
| URI: | https://pred.uni-regensburg.de/id/eprint/45295 |
Actions (login required)
 |
View Item |
